Fundamental Analysis Discussion Only (IXC Thread), page-36

Agree. IMO, they'll sell the asset post this P3 read-out. I don't see any point raising funding to conduct another P3 trial themselves to satisfy the FDA. They should be able to attract a decent offer before then. The buyer can take the asset to market in UK/Europe, generate substantial revenue, and potentially use some of those funds to cover the P3 FDA-targeting trial. Plus, there is a paediatric IIH indication to pursue (this will be expedited with positive P3 EMA result) and at least one other adult indication to pursue. The good news is that even if they don't sell the asset post this P3 read-out, then we still have a revenue generating product with a > $1B TAM in UK/Europe - with one adult indication.